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UK Biobank is a prospective cohort study with 500,000 participants aged 40 to 69. Recently an enhanced imaging
study received funding. Cardiovascular magnetic resonance (CMR) will be part of a multi-organ, multi-modality
imaging visit in 3–4 dedicated UK Biobank imaging centres that will acquire and store imaging data from 100,000
participants (subject to successful piloting). In each of UK Biobank’s dedicated bespoke imaging centres, it is
proposed that 15–20 participants will undergo a 2 to 3 hour visit per day, seven days a week over a period of
5–6 years. The imaging modalities will include brain MRI at 3 Tesla, CMR and abdominal MRI at 1.5 Tesla, carotid
ultrasound and DEXA scans using carefully selected protocols. We reviewed the rationale, challenges and proposed
approaches for concise phenotyping using CMR on such a large scale. Here, we discuss the benefits of this imaging
study and review existing and planned population based cardiovascular imaging in prospective cohort studies. We
will evaluate the CMR protocol, feasibility, process optimisation and costs. Procedures for incidental findings, quality
control and data processing and analysis are also presented. As is the case for all other data in the UK Biobank
resource, this database of images and related information will be made available through UK Biobank’s Access
Procedures to researchers (irrespective of their country of origin and whether they are academic or commercial)
for health-related research that is in the public interest.
Keywords: Cardiovascular magnetic resonance, Prospective cohort study, Population-based study, Nested-case
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The challenges of understanding the determinants of
common life-threatening and disabling diseases, such as
myocardial infarction and stroke, are substantial. Such
conditions are typically caused by many different risk
factors that each have moderate effects and interact with
each other in complex ways. Prospective cohort studies
allow risk factors to be assessed before disease or its
management affects participants, while diseases can also
be assessed that are not readily investigated by retro-
spective studies. Prospective studies do, however, require* Correspondence: s.e.petersen@qmul.ac.uk
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reproduction in any medium, provided the orinvolvement of large numbers of participants because only
a relatively small proportion will develop a particular con-
dition. When it is known which individuals have devel-
oped some particular condition then detailed analyses (e.g.
of stored images) can be focused on them and on matched
controls in so-called “nested” case–control studies.
This review describes the rationale, the challenges and
the approaches of performing cardiovascular magnetic
resonance imaging scans, as part of a multi-organ multi-
modality imaging visit, on 100,000 of the 500,000 parti-
cipants in the UK Biobank prospective cohort study.
UK Biobank and CMR: current state and how did we get
there?
UK Biobank (www.ukbiobank.ac.uk) has involved the col-
lection of extensive baseline questionnaire data, physicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and women aged 40–69 at baseline between 2006 and
2010 in 22 centres across the UK. UK Biobank’s scientific
protocol and operational procedures were reviewed and
approved by the North West Research Ethics Committee
(REC Reference Number: 06/MRE08/65). Participants’
health is now being followed long-term through linkage to
health record systems and re-contact with participants.
When reviewing the UK Biobank protocol in July 2006,
the International Peer Review Panel recommended that
more intensive phenotyping be conducted among large
subsets of the cohort, including more detailed imaging
assessments.
Since 2008, the UK Biobank Enhancement Working
Group has invited imaging experts of different specialities
to advise on their respective fields. From these experts,
the UK Biobank’s Imaging Working Group emerged. The
imaging experts were provided with the following brief: to
build the strongest scientific case for using certain imaging
modalities and protocols so that imaging can be achieved
in 100,000 of the 500,000 UK Biobank subjects as part of
a comprehensive enhancement visit, including imaging of
at least the brain, heart, whole body, carotid arteries,
bones and joints. The rationale for 100,000 participants is
based on the requirement for 5,000 to 10,000 cases of
some particular disease to allow reliable detection of odds
ratios of about 1.5 to 1.3 for associations with various risk
factors. For example: for the combination of myocardial
infarction and death related to coronary artery disease,
the expected numbers of incident disease occurring dur-
ing follow-up of 100,000 imaged participants in UK
Biobank would be 3,000, 6,000 and 10,000 in 2020
(5 year follow-up), 2025 (10 year follow-up) and 2030
(15 year follow-up), respectively.
In May 2009 UK Biobank submitted a proposal for
various enhancements to the baseline visit that also in-
cluded a proposal for conducting imaging assessments
in dedicated regional centres. At that time, the funders
deferred judgement on the imaging enhancement and
recommended UK Biobank develop their imaging con-
cept by wide-ranging consultation with the scientific im-
aging community. During the past few years, the
Imaging Working Group has consulted extensively with
imaging experts throughout the UK and internationally
in a number of meetings and online discussions and
established several international expert advisory groups
(e.g. the CMR advisory group). The focus of the con-
sultation process was to select and justify the most suit-
able imaging modalities and protocols. Additionally, the
working group also discussed and developed plans of
how best to store data, how to make data accessible for
image analysis and how to ensure quality control.
Advisory groups for each imaging modality were tasked
with developing protocols that would maximise theamount of relevant information obtained while fitting into
per-participant time constraints that would allow imaging
on a large scale. The Imaging Working Group has been
responsible for developing the detailed research protocol
and, in collaboration with UK Biobank, has been success-
ful in being awarded the funding to start this imaging pro-
ject of unprecedented scale. The project is planned in two
stages: the first phase will take place over 12 to 18 months
in one centre involving approximately 6,000 subjects to
pilot feasibility and gather evidence related to the proce-
dures of management of incidental findings. If successful,
then the second phase will take place in 3–4 imaging cen-
tres to complete the imaging in 100,000 participants over
a 5–6 year period.
Choice of cardiovascular imaging modality
The brief described above was presented to the imaging
experts to advise on which modality or modalities would
be best to achieve large-scale cardiovascular phenotyping
as part of a multi-organ imaging assessment. This led to
the further refinement of a framework which focuses on
the following: 1) the safety and comfort of participants
was considered essential; 2) the combined visit should
not exceed 3 hours; 3) a recruitment rate of at least 20%
would need to be achieved with a low rate of non-
compliance or drop-out during the visit and 4) for cost-
effectiveness and quality control reasons, imaging would
need to take place in dedicated UK Biobank regional im-
aging centres using uniform equipment rather than a
hospital setting. From this framework, the following list
of requirements regarding the cardiovascular imaging
modality was developed: the test would need to be non-
invasive, not use radiation, should not require the ad-
ministration of medications or contrast agents, last at
most 20 minutes, parameters acquired should be repro-
ducible, and include the most relevant quantifiable car-
diovascular imaging parameters.
As cardiac CT uses radiation and would require con-
trast administration and often beta blockade for CT co-
ronary angiography, this modality was not considered
further for this population-based setting. Extensive discus-
sions were held around whether echocardiography, CMR
or both should be recommended. Following expert pre-
sentations to the UK Biobank International Scientific Ad-
visory Board meeting in 2011, the decision was made to
support CMR alone as part of the imaging assessment.
This decision was based on the better reproducibility of
CMR (which is also beneficial for the power of the study),
the likelihood of better quality control, and the number
and importance of the relevant cardiovascular parameters
that can be derived with a 20-minute protocol. The main
arguments for echocardiography were based around lower
cost and imaging of valve structure and function. For this
large-scale high-throughput model, however, the marginal
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pared to echocardiography was estimated to be approxi-
mately £50/subject only and valve pathology, a strength of
echocardiography, was not considered as relevant for the
UK Biobank population as the CMR derived parameters.
Existing prospective cohort studies using CMR
Previous cohort studies with CMR have involved only a
few thousand participants (Table 1); studies of this size are
mainly designed to estimate the prevalence of disease and
of risk factors since too few of the participants subse-
quently develop any particular condition to study the as-
sociations of risk factors with subsequent disease. The
largest published population-based investigation that in-
volves CMR is the Multi-Ethnic Study of Atherosclerosis
(MESA). In this multicentre cohort study, 5004 asymp-
tomatic individuals from four ethnic groups in the USA
have had traditional CMR measures of left and right ven-
tricular (LV/RV) mass, volume and function and aortic
function. Subgroups have also had additional CMR mo-
dalities, including: tagging to assess regional wall motion,
contractility and relaxation (about 1200 participants);
contrast-enhanced perfusion CMR (n = 222); and coronary
artery MR (n = 180). Study participants were enrolled
from 2000–2002, and most of the analyses derived from
these CMR data have been cross-sectional. For example,
MESA has examined the gender and ethnic distributions
of LV and RV volume, mass and ejection fraction [1,2],
and associations of traditional and novel cardiovascular
risk factors (such as inflammatory markers) with global
and regional systolic and diastolic cardiac function [3-11].
Novel associations have been identified between cardio-
vascular risk factors and CMR parameters [12,13]. Since
multiple imaging modalities were included, MESA al-
lows the comparison of CMR findings to coronary ar-
tery calcium (CT scanning) and carotid intimal media
thickness [14]. MESA has shown high reproducibility
of tagging [15], and associations between vascular func-
tion, cardiac function and myocardial blood flow [16-19].
The 10-year follow-up of MESA has recently been com-
pleted, enrolling approximately 3013 of the original 5004Table 1 Previously developed prospective population studies
with CMR imaging (including at least 1000 participants)
Age of
cohort (y)
MRI brain CMR MRI body
Jackson Heart Study 35-84 2,000
SHIP 20-79 4,000 4,000
MESA 45-84 5,000
Framingham Heart Study 38-88 2,500 1,800
Dallas Heart Study 18-65 3,000 3,000 3,000
AGES Reykjavik >70 5,000 1,000
CMR: Cardiovascular Magnetic Resonance.CMR participants. Of these, 1839 subjects had gadolinium
enhanced CMR studies.
The Dallas Heart Study involves CMR at 1.5 Tesla
in 3000 people aged 18 to 65 years from a multi-
ethnic population in which global LV function, vol-
umes, mass and gradient echo cine sequences (which
are now outdated) have been measured in over 90% of
subjects [20-22]. The East German population-based
Study of Health in Pomerania (SHIP) is currently acqui-
ring whole-body MRI at 1.5 T in approximately 4000
healthy participants aged 20 to 79 years. The CMR aspect
involves the assessment of global and regional cardiac
function, with optional late gadolinium enhancement to
identify myocardial scar or fibrosis [23,24]. The Jackson
Heart Study is currently acquiring CMR scans in about
2000 African-Americans aged 35–84 years. The measures
include the assessment of global and regional cardiac
function, late gadolinium enhancement to identify myo-
cardial scar or fibrosis and measures of aortic structure
and function.
Enhanced phenotyping with multi-modality, multi-organ
imaging in UK Biobank
Following the consultation process described above, the
agreed imaging enhancement visit will include MRI of the
brain, heart, aorta, abdomen and carotid ultrasound and
Dual-energy X-ray absorptiometry (DEXA). By contrast
with previous studies, the integration of large-scale data in
UK Biobank from imaging one part of the body with im-
aging data from other parts of the body, as well as with
the detailed non-imaging data (environmental factors, ge-
notypes etc.) that have already been collected, will support
a unique approach to the investigation of the biological
mechanisms of disease. For example, cognitive decline
(such as dementia) may be related to risk factors derived
not only from the brain, but also from the heart (e.g. varia-
tions in structure and function [25-27], arteries, carotid
plaques [28-30], body fat [31], bones and joints [32]).
Identifying these intertwining risk factors will be made
possible with the use of the UK Biobank multi-modality
imaging resource.
CMR approach in UK Biobank
The CMR protocol was developed bearing in mind the
framework and requirements. Each participant will
undergo a 20-minute CMR protocol, as part of a 30-
minute combined CMR and abdominal MRI protocol,
using a 1.5 Tesla scanner that will include steady state
free precession cine imaging in long axis, ventricular
and atrial short axes and axial planes through the
aorta, myocardial tagging and aortic flow sequences.
This protocol will allow the determination of the mini-
mum dataset in Table 2. Each participant’s visit would also
include a 30-minutes brain MRI at 3 Tesla, a DEXA scan
Table 2 Minimum dataset of parameters that will be able to be derived from images acquired in UK Biobank CMR
protocol
Cardiovascular
structure
Quantifiable parameters
Left ventricle Myocardial mass (g), ejection fraction (%), end-diastolic volume (ml), end-systolic volume (ml), stroke volume (ml) and the
corresponding values indexed to body surface area, height or weight. Time to peak contraction and filling rates (both in s)
and peak contraction and filling rates (both in ml/s). American Heart Association (AHA) myocardial segments: end-diastolic
thickness (mm), end-systolic thickness (mm), thickening (mm), thickening (%). Strain: strain (%) and strain-rates (1/s) in three
directions (radial [ERR], circumferential [ECC] and longitudinal [ELL]) and in systole and diastole and corresponding changes in
angle caused by shear (ERC, ERL and ECL).
Right ventricle Myocardial mass (g), ejection fraction (%), end-diastolic volume (ml), end-systolic volume (ml), stroke volume (ml) and the
corresponding values indexed to body surface area, height or weight.
Left atrium End-diastolic volume (ml), end-systolic volume (ml), stroke volume (ml), ejection fraction (ml) and left atrial diameters as
typically measured by 2D-echocardiography approaches.
Right atrium End-diastolic volume (ml), end-systolic volume (ml), stroke volume (ml), ejection fraction (ml) and right atrial diameters as
typically measured by 2D-echocardiography approaches.
Aorta Distensibility (1/mmHg) in ascending aorta, proximal descending and distal descending aorta; diastolic aortic dimensions
(cm2): ascending aorta, proximal descending and distal descending aorta. Proximal, distal and total pulse wave velocity (m/s).
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nutes) in addition to preparation (including consenting)
and collection of non-imaging data and biological samples
(e.g. partial repeat of the baseline assessment visit with
supplementary cognitive function tests). The notional lay-
out of a dedicated UK Biobank imaging centre is displayed
in Figure 1.
UK Biobank’s Cardiovascular MRI Advisory Group will
continue to advise on data acquisition, radiographer train-
ing and quality control, as well as providing guidance on
subsequent applications for research uses. The CMR
protocol is subject to modifications before, during and im-
mediately after the pilot phase, but it is not likely to be
changed subsequently during the main phase of the study.
Examples of opportunities for modification include auto-
mated plane finding algorithms or full 3D volumetric ac-
quisition of the heart [33]. CMR feature tracking, which is
similar to echocardiographic speckle tracking, tracks re-
gional myocardial features throughout the cardiac cycle.
This technique allows myocardial strain measurements to
be derived without the need for additional imaging se-
quences (such as tagging) because features are tracked
from clinically standard steady-state free precession
(SSFP) sequences [34]. If CMR feature tracking is suffi-
ciently validated and robust when the UK Biobank im-
aging assessments take place then it may be possible to
remove the tagging sequences from the protocol and
use that time for other sequences (such as mitral and
aortic flow sequences or non-contrast T1 mapping tech-
niques, which have recently been shown to be highly re-
producible and differentiate between healthy controls
and patients with cardiomyopathies) [35-38].
There was agreement among the experts consulted
that this non-contrast CMR protocol would not benefit
in quality from using a magnetic field strength above
1.5 T. Higher field strengths would render it moreexpensive and less feasible, largely due to prolonged
image optimisation and shimming requirements. Con-
trast agent sequences would provide important extra in-
formation (e.g. myocardial blood flow, myocardial
fibrosis/scar and LV thrombus), but experts agreed it
was not feasible to include MR-contrast in such a large
population-based study. In particular, there was a risk
(albeit small) of serious adverse events: among 100,000
participants, at least one death and up to 1000 other ser-
ious adverse reactions (depending on the definition)
might be expected if contrast agents were administered.
Other reasons for not using contrast included complex-
ity of scan acquisition, associated technologist training
needs and potential effect on brain MRI scans.
Feasibility, process optimisation and costs
The imaging protocols are all based on established tech-
nologies and each has been pre-piloted to confirm its
feasibility within the time constraints. Modelling indi-
cates that 100,000 participants could be imaged within
6 years in 3–4 dedicated imaging centres. A 12 – 18 month
pilot phase will first be conducted in one of the imaging
centres to establish optimal participant response rates,
imaging assessment throughput, and data storage. Partici-
pants’ understanding of the consent process and procedure
for feedback of incidental findings will also be evaluated in
the pilot. This would be followed by a main phase of 5 years
with 3–4 concurrently operating dedicated UK Biobank
imaging centres (Table 3). The target is to image 21 partici-
pants per centre per day using a complex buffered ap-
proach (Figure 2) and imaging centres operating for
14 hours per day, 7 days per week. The numbers of staff
with different levels of expertise required to achieve such a
throughput in a shift system is summarised in Table 4.
Subject to successful piloting in 2013/14 at a cost of
about £10 M (which includes the full capital costs for
Figure 1 Dedicated UK Biobank imaging centre layout.
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phase of imaging assessments would be conducted
during 2014–2018 at a further cost of about £27 M,yielding 100,000 participants with imaging enhance-
ments at a total cost of £37 M. This cost works out at
less than £400 per participant for all of the different
Table 3 Estimated number of participants to be imaged and operational duration in each of the three imaging centres
for the UK Biobank imaging enhancement
Total number of
participants recruited
in baseline
Approximate
anticipated
attendance rate
Recruited participants Centre operational
duration (years)
Total duration of
Project (years)
Pilot Main Total Pilot Main Total
North 150,601 25.0% 8,5201 29,130 37,650 1.5 4.1 5.6 -
South 155,545 - 38,886 38,886 - 5.5 5.5 -
N. East + Scotland 94,233 - 23,558 23,558 - 3.3 3.3 -
400,379 100,095 14.42 7.0
1 Assumes the pilot processes an average of 16 participants a day, and operates 355 days of the year for 18 months.
2 Assumes we can process an average of 20 participants a day for the main study, operating 355 days of the year.
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of imaging in previous epidemiological studies. In par-
ticular, the CMR component is less than £100, which
compares favourably to the much higher costs of clin-
ical CMR studies.
These relatively low costs can only be achieved through
the specific UK Biobank imaging centre set-up. These im-
aging centres (Figure 1) will be rented or purpose-built on
the basis of feasibility and cost of scanning 100,000 partic-
ipants. Factors influencing the choice of location includeFigure 2 Representation of participant flow with complex buffered preasonable distance to participants’ homes, transport con-
nections, power supply, building or renting costs.
Quality control of CMR images
One of the most important requirements for the success
of a massive-scale imaging study such as UK Biobank
imaging enhancements is a vigorous, accountable and
sustained quality control process. The radiographers will
have extensive training on the imaging platform pro-
vided by the vendor. Prior to the start of the pilot phase,rocess for groups of 3 participants.
Table 4 Estimated staffing mix needed for a single imaging centre
Staff role and grade Responsibility Number
Manager (NHS Band 9) Day-to-day management, training, support, efficient operation of the centre, participant assessment 3
Radiographer (NHS Band 8) Brain/cardiac/abdominal MR imaging 10
Technician (NHS Band 6) DXA and 3D carotid ultrasound 3
Receptionist Participant welcome, registration and visit coordination 5
Staff “number” refers a pool of staff working shifts to cover 14 hour day and seven day week operation.
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volume CMR unit, including observation and hands-on
CMR acquisition. Subsequently, these radiographers will
be trained in the imaging centre set-up for UK Biobank
before starting to work in the pilot phase or in the main
phase of imaging enhancements. The radiographers will
perform quality checks of the images that are obtained
(up to about 10% of images during the initial pilot phase,
but likely to decrease to 2-5% with greater experience).
Some time from a dedicated MR physicist and CMR
consultant will be supported for review of subsets of the
images. The MR physicist will arrange regular MR phan-
tom measurements as part of quality control procedures.
The CMR consultant will visit the imaging centres regu-
larly to ensure acquisition standards are met and to pro-
vide additional training on site as necessary. Radiographers
for the additional dedicated imaging centres during the
main phase will be trained in the pilot phase imaging
centre.
Data processing and access procedures
It is intended to apply available automated analysis tools
to the imaging data at the time of collection and to con-
duct detailed non-automated analyses only subsequently
in a targeted way. So, for example, when sufficient num-
bers of people have developed some particular condition,
specific analyses would be conducted of the relevant par-
ticipant images and matched controls. Such nested case–
control comparisons would provide most of the statistical
information about the association of particular image-
related factors with the particular health outcome, while
being much more cost-effective than conducting non-
specific image analyses in all participants at the time of
image collection. In addition, it is likely that CMR image
analysis during the next 5–10 years will become more
automated and cheaper, and that recommendations to
standardise image analysis will be published.
Researchers will be able to apply for access to image
data for specific scientific questions in accordance with
UK Biobank’s Access Procedures (www.ukbiobank.ac.uk).
There is a two stage application process involving a review
by UK Biobank of the preliminary application and the
provision of a suitable quote (which is intended to assist
researchers with the writing of a grant to cover such
costs). Quotes will include costs – charged on a costrecovery basis by UK Biobank - for gaining access to im-
ages for analysis, for requesting image data that have
already been analysed and for requesting other variables
from the tests and questionnaires in UK Biobank. If re-
searchers are granted access to UK Biobank data or im-
ages, they are obliged to return the results of their analysis
to UK Biobank’s database following the completion of their
project. In turn, this will result in the creation of a more
detailed resource of imaging information within UK
Biobank, which will be able to be accessed by other
researchers.
UK Biobank CMR imaging provides a platform for
new opportunities. Recent advances in machine learning
algorithms are providing encouraging results that indi-
cate that entirely automated analysis of cardiac function
may be available even within the initial phases of the UK
Biobank imaging enhancements [39]. The Cardiac Atlas
Project combined images and results from MESA and
the Jackson Heart Study to enable meta-analyses of
probabilistic cardiac shape and function patterns [40,41].
This could be extended to the larger number of partici-
pants in UK Biobank. By mapping the regional function
of the heart using consistent coordinates, mathematical
models of heart shape and motion can be used to form
an atlas of regional shape and motion.
Incidental findings
A significant challenge for large-scale, and in particular
multi-organ, imaging studies in a mostly healthy popula-
tion living in the community is how to deal with incidental
findings [42]. It is beyond the scope of this review to pro-
vide an in-depth analysis of the legal and ethical issues re-
lated to dealing with incidental or unexpected findings.
However, a recent report by representatives of research
imaging centres, which included professional societies,
regulatory bodies, funding organisations and patient orga-
nisations in the UK, summarises the position succinctly
“the challenge is to strike the correct balance between
answering the research question and the welfare of the
participant… Research to clarify these issues is vital for de-
veloping evidence-based policies for the management and
feedback of incidental findings” [43].
The approach to incidental findings proposed by UK
Biobank has been very carefully considered and took into
account evidence from literature reviews, experiences
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discussions with the Royal College of Radiologists and the
Society and College of Radiographers and legal advice. In
addition, input was obtained from UK Biobank’s inde-
pendent Ethics & Governance Council. UK Biobank’s
provisional approach will be to provide limited feedback
for incidental findings considered to be potentially
‘serious’ (defined in this context as likely to threaten life
span, quality of life or major body functions) that are ob-
served during the data acquisition or quality control stage.
The feedback loop provides for review by expert radiolo-
gists and then, if appropriate, feedback will be provided to
the participant and his/her general practitioner. This
approach to imaging incidental findings is consistent
with – but more detailed than - the standard operating
procedure on incidental findings used in the baseline UK
Biobank assessment visit. Further, since the imaging pro-
cedures increase the potential likelihood for serious inci-
dental findings to be observed, detailed standard operating
procedures will be developed and then tested during the
pilot study. Participants will be given detailed and explicit
information about the imaging assessment (including the
approach to feedback of incidental findings) before giving
consent. Their understanding of UK Biobank’s approach
and its impact on them and the wider health community
(including induced healthcare costs) will also be assessed
carefully during the pilot phase.Conclusions
This review describes the rationale, challenges and pro-
posed approaches for the imaging enhancements of the
UK Biobank population based cohort study involving
multiple imaging modalities including brain, body com-
position, bone, joints and, as focussed on here, heart and
large blood vessels. This large-scale study is intended to
provide sufficient statistical power for reliable assessment
of associations between these imaging phenotype mea-
sures and a wide range of incident diseases. As with the
successful recruitment and baseline assessment phase of
UK Biobank, the application of industrial processes to op-
timise and manage these imaging assessments will allow
them to be conducted cost-efficiently. The pilot phase
during 2013/14 is intended to develop streamlined proce-
dures and confirm feasibility and costs. The main phase is
intended to take place during 2014–2018.
As is the case for the data within the UK Biobank re-
source, all imaging data will be available to bona fide
researchers conducting health-related research that is in
the public interest.
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